A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
Launched by BARBARA ANN KARMANOS CANCER INSTITUTE · Jun 26, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help cancer care providers talk with their patients about the costs of treatment. The goal is to reduce the financial stress, often called “financial toxicity,” that many patients face during cancer care. The study is testing a communication program designed to improve how doctors, nurses, and other cancer care team members discuss treatment costs with patients. If successful, this program could work alongside a patient-focused app called DISCO that helps patients understand and manage these costs.
The trial is open to cancer care providers at the Karmanos Cancer Institute and Wayne State University who work directly with patients, including doctors, nurses, social workers, and advanced practice providers. Participants will complete a survey at the beginning and take part in two one-on-one meetings. These meetings will help develop and test the new communication program. This study is currently recruiting, and anyone working in these roles at the specified clinics may be eligible to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Oncology care providers at Karmanos Cancer Institute (KCI)/Wayne State University(WSU) including medical oncologists, nurses, social workers and advance practice providers who treat cancer patients at KCI Detroit or Farmington Hills clinics
- Exclusion Criteria:
- • -
About Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute, a leading nonprofit cancer research and treatment center located in Detroit, Michigan, is dedicated to advancing innovative cancer therapies and improving patient outcomes through rigorous clinical trials. Affiliated with Wayne State University, the institute emphasizes a multidisciplinary approach, integrating cutting-edge research with compassionate patient care. With a commitment to translating laboratory discoveries into effective treatments, Karmanos plays a pivotal role in the national landscape of cancer research, focusing on personalized medicine and the development of novel therapeutic strategies to combat various forms of cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Patients applied
Trial Officials
Lauren M Hamel, PhD
Principal Investigator
Wayne State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported